A phase II study of tandutinib (MLN518) in androgen-independent prostate cancer with bone metastases.
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2013
At a glance
- Drugs Tandutinib (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Feb 2008 Status changed from recruiting to in progress according to NCT.